|
99mTc-MIBI显像联合超声对乳腺癌新辅助化疗疗效的评估
|
Abstract:
本文探讨99mTc-MIBI显像联合彩色多普勒超声诊断与临床触诊法在乳腺癌新辅助化疗(neoadjuvant chemotherapy, NAC)疗效评估的应用价值。研究对象为70例未接受手术的乳腺癌患者(76个病灶),分别在NAC化疗前和进行2~3疗程化疗后进行临床触诊、彩色多普勒超声以及99mTc-MIBI显像检查。以99mTc-MIBI显像的核素肿瘤反应(STR) > 30%为有效标准,临床疗效参照WHO标准评价。以NAC后手术切除病理反应为标准,以I级定为无效,II、III级定为有效。99mTc-MIBI显像法检查NAC化疗前后乳腺癌患者的放射性计数比值(T/N),NAC化疗有效者45例,其T/N值前后分别为3.326 ± 1.119和1.996 ± 0.792,差异有统计学意义(t = 19.986, p < 0.001);NAC化疗无效者31例,其T/N值前后分别为3.001 ± 1.153和2.434 ± 1.104,差异有统计学意义(t = 8.181, p < 0.001)。病理评价II级~III级的60例乳腺癌患者,T/N值经过NAC化疗前后存在显著性差异,具有统计学意义(p < 0.001),而病理评价I级的16例乳腺癌患者经NAC化疗前后T/N值无显著性变化,无统计学意义(p = 0.342 > 0.05)。99mTc-MIBI显像法、彩色多普勒超声诊断法和临床触诊法评价NAC疗效的敏感度、特异度和准确度分别为87.500%、89.286%、88.158%,80.851%、82.759%、81.579%,72.727%、75.001%、73.750%。以病理检查为标准,99mTc-MIBI显像评价NAC疗效的灵敏度、特异性和准确性高于彩色多普勒超声诊断法和临床触诊法,后续对乳腺癌患者可进行99mTc-MIBI显像与彩色多普勒超声共同检查,提高NAC疗效评估的准确性。
This study aims to explore the effectiveness of combining 99mTc-MIBI scintigraphy with color Doppler ultrasound diagnosis and clinical palpation for evaluating the efficacy of neoadjuvant chemotherapy (NAC) in treating breast cancer. The study included 70 cases of non-operated breast cancer patients with a total of 76 lesions. Clinical palpation, color Doppler ultrasound, and 99mTc-MIBI scintigraphy were conducted before NAC chemotherapy and after 2~3 courses of chemotherapy. In the assessment, a tumor response (STR) of >30% based on 99mTc-MIBI imaging was considered effective, and the clinical efficacy was evaluated according to the WHO criteria. The post-NAC surgical pathological response was used as the standard, with Grade I defined as ineffective and Grades II and III as effective. The study assessed the radiotracer uptake ratio (T/N) in breast cancer patients before and after neoadjuvant chemotherapy (NAC) using 99mTc-MIBI scintigraphy. The result indicated that the effective cases of NAC chemotherapy were 45 (n = 45), and the T/N values before and after treatment were 3.326 ± 1.119 and 1.996 ± 0.792, respectively, with a statistically significant difference observed (t = 19.986, p < 0.001). The result demonstrated that NAC chemotherapy was ineffective (n = 31), the T/N values before and after treatment were 3.001 ± 1.153 and 2.434 ± 1.104, respectively, showing a statistically significant difference (t = 8.181, p < 0.001). Among the 60 patients with pathological grade
[1] | Siyang, C., Xia, L., Junwei, C., et al. (2021) Feasibility and Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Axillary Nodes at Initial Diagnosis: An Up-to-Date Meta-Analysis of 3,578 Patients. The Breast, 59, 256-269. https://doi.org/10.1016/j.breast.2021.07.015 |
[2] | Nikyar, N., Tegnelius, E., Valachis, A., et al. (2022) Adjuvant Locoregional Radiation Therapy in Breast Cancer Patients with Pathologic Complete Response after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis. Clinical and Translational Radiation Oncology, 33, 45-52. https://doi.org/10.1016/j.ctro.2021.12.010 |
[3] | 刘波. 新辅助化疗后腋窝淋巴结转阴乳腺癌患者前哨淋巴结活检研究[D]: [硕士学位论文]. 青岛: 青岛大学附属医院乳腺病诊疗中心, 2020. |
[4] | Tarantino, P., Gandini, S., Trapani, D., et al. (2021) Immunotherapy Addition to Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Critical Reviews in Oncology/Hematology, 159, 103223. https://doi.org/10.1016/j.critrevonc.2021.103223 |
[5] | 刘亭, 王玉涛, 汪建华, 等. 99mTc-MIBI单光子显像早期评价乳腺癌新辅助化疗的实验研究[J]. 现代实用医学, 2020, 32(12): 1481-1483 1438 1583. |
[6] | 孔丹, 关晏星. 影像方法在乳腺癌新辅助化疗疗效评价中的应用[J]. 南昌大学学报(医学版), 2010, 50(11): 116-119. |
[7] | 贾莉, 邹天宁, 夏正武, 等. 99mTc-MIBI乳腺显像评价乳腺癌新辅助化疗效果的临床价值[J]. 现代医学, 2014, 42(1): 4-8. |
[8] | 杨吉琴. 99Tcm-MIBI SPECT/CT断层融合显像在评价乳腺癌新辅助化疗效果中的增益价值[J]. 中国医学影像学杂志, 2017, 25(11): 820-824. |
[9] | 李学兵, 牛静, 王晋, 等. 99mTc-3PRGD2 SPECT/CT显像半定量参数与乳腺癌分子分型及病理的相关性[J]. 分子影像学杂志, 2023, 46(2): 342-346. |
[10] | 刘洪彪, 占宏伟, 孙达, 等. 乳腺99Tcm-MIBI闪烁显像和X线摄影诊断乳腺癌的临床价值比较研究[J]. 实用肿瘤杂志, 2020, 35(4): 360-366. |
[11] | 杨亲亲, 严丽霞, 尹红艳, 等. 超声和99mTc-MIBI乳腺专用伽玛显像对早期乳腺癌的鉴别诊断价值[J]. 中国临床医学, 2022, 29(5): 830-836. |
[12] | 刘斌, 李玉琴, 黄蕊, 等. 99mTc-MIBI SPECT/CT及颈部超声在原发性甲状旁腺功能亢进症术前诊断中的应用[J].分子影像学杂志, 2022, 45(4): 595-598. |
[13] | 张勇, 陆永萍, 周红, 等. 超声弹性成像和99mTc-MIBI核素显像对乳腺癌诊断的价值比较[J]. 中国实用医药, 2013, 8(6): 14-15. |
[14] | 卢峰, 张开炯, 吴立春, 等. 基于检验组学及机器学习的乳腺癌诊断模型研究[J]. 现代肿瘤医学, 2024, 32(7): 1264-1272. |
[15] | 王瑞琦, 马晓娟, 牛逸凡, 等. 人工智能在乳腺癌超声诊断中的应用进展[J]. 中国医药, 2023, 18(6): 945-948. |
[16] | 刘瑶. 99mTc-HFAPI-SPECT/CT在乳腺癌及其腋窝淋巴结转移诊断中的临床价值[D]: [硕士学位论文]. 吉林: 吉林大学中日联谊医院, 2020. |
[17] | 孔丹. 99mTc-MIBI显像在乳腺癌新辅助化疗疗效评价中应用及与临床法、B超法比较[D]: [硕士学位论文]. 南昌:南昌大学, 2011. |